Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer: A 3-Year Prospective Cohort Study

Danbee Kang, Im Ryung Kim, Eun Kyung Choi, Young Hyuck Im, Yeon Hee Park, Jin Seok Ahn, Jeong Eon Lee, Seok Jin Nam, Hae Kwang Lee, Ji Hye Park, Dong Youn Lee, Mario E. Lacouture, Eliseo Guallar, Juhee Cho

Research output: Contribution to journalArticle

Abstract

Background: Although chemotherapy-induced alopecia (CIA) is considered temporary, some patients report persistent alopecia several years after chemotherapy. There is, however, a paucity of long-term prospective data on the incidence and impact of permanent CIA (PCIA). The objective of our study was to estimate the long-term incidence of PCIA in a cohort of patients with breast cancer whose hair volume and density were measured prior to chemotherapy and who were followed for 3 years after chemotherapy. Materials and Methods: Prospective cohort study of consecutive patients ≥18 years of age with postoperative diagnosis of stage I–III breast cancer expected to receive adjuvant chemotherapy at the outpatient breast cancer clinic at the Samsung Medical Center in Seoul, Korea, from February 2012 to July 2013 (n = 61). Objective hair density and thickness were measured using a noninvasive bioengineering device. Results: The proportion of participants who had PCIA at 6 months and 3 years was 39.5% and 42.3%, respectively. PCIA was characterized in most patients by incomplete hair regrowth. Patients who received a taxane-based regimen were more likely to experience PCIA compared with patients with other types of chemotherapy. At a 3-year follow-up, hair thinning was the most common problem reported by study participants (75.0%), followed by reduced hair volume (53.9%), hair loss (34.6%), and gray hair (34.6%). Conclusion: PCIA is a common adverse event of breast cancer adjuvant cytotoxic chemotherapy. Clinicians should be aware of this distressing adverse event and develop supportive care strategies to counsel patients and minimize its impact on quality of life. Implications for Practice: Knowledge of permanent chemotherapy-induced alopecia, an under-reported adverse event, should lead to optimized pretherapy counseling, anticipatory coping techniques, and potential therapeutic strategies for this sequela of treatment.

Original languageEnglish (US)
JournalOncologist
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Alopecia
Hair
Cohort Studies
Prospective Studies
Drug Therapy
Breast Neoplasms
Adjuvant Chemotherapy
Bioengineering
Incidence
Korea
Breast Cancer 3
Counseling
Outpatients
Quality of Life
Equipment and Supplies
Therapeutics

Keywords

  • Alopecia
  • Breast neoplasm
  • Chemotherapy
  • Cohort

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Kang, D., Kim, I. R., Choi, E. K., Im, Y. H., Park, Y. H., Ahn, J. S., ... Cho, J. (Accepted/In press). Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer: A 3-Year Prospective Cohort Study. Oncologist. https://doi.org/10.1634/theoncologist.2018-0184

Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer : A 3-Year Prospective Cohort Study. / Kang, Danbee; Kim, Im Ryung; Choi, Eun Kyung; Im, Young Hyuck; Park, Yeon Hee; Ahn, Jin Seok; Lee, Jeong Eon; Nam, Seok Jin; Lee, Hae Kwang; Park, Ji Hye; Lee, Dong Youn; Lacouture, Mario E.; Guallar, Eliseo; Cho, Juhee.

In: Oncologist, 01.01.2018.

Research output: Contribution to journalArticle

Kang, D, Kim, IR, Choi, EK, Im, YH, Park, YH, Ahn, JS, Lee, JE, Nam, SJ, Lee, HK, Park, JH, Lee, DY, Lacouture, ME, Guallar, E & Cho, J 2018, 'Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer: A 3-Year Prospective Cohort Study', Oncologist. https://doi.org/10.1634/theoncologist.2018-0184
Kang, Danbee ; Kim, Im Ryung ; Choi, Eun Kyung ; Im, Young Hyuck ; Park, Yeon Hee ; Ahn, Jin Seok ; Lee, Jeong Eon ; Nam, Seok Jin ; Lee, Hae Kwang ; Park, Ji Hye ; Lee, Dong Youn ; Lacouture, Mario E. ; Guallar, Eliseo ; Cho, Juhee. / Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer : A 3-Year Prospective Cohort Study. In: Oncologist. 2018.
@article{6ce542d21cab4a78a939e1cf49a00283,
title = "Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer: A 3-Year Prospective Cohort Study",
abstract = "Background: Although chemotherapy-induced alopecia (CIA) is considered temporary, some patients report persistent alopecia several years after chemotherapy. There is, however, a paucity of long-term prospective data on the incidence and impact of permanent CIA (PCIA). The objective of our study was to estimate the long-term incidence of PCIA in a cohort of patients with breast cancer whose hair volume and density were measured prior to chemotherapy and who were followed for 3 years after chemotherapy. Materials and Methods: Prospective cohort study of consecutive patients ≥18 years of age with postoperative diagnosis of stage I–III breast cancer expected to receive adjuvant chemotherapy at the outpatient breast cancer clinic at the Samsung Medical Center in Seoul, Korea, from February 2012 to July 2013 (n = 61). Objective hair density and thickness were measured using a noninvasive bioengineering device. Results: The proportion of participants who had PCIA at 6 months and 3 years was 39.5{\%} and 42.3{\%}, respectively. PCIA was characterized in most patients by incomplete hair regrowth. Patients who received a taxane-based regimen were more likely to experience PCIA compared with patients with other types of chemotherapy. At a 3-year follow-up, hair thinning was the most common problem reported by study participants (75.0{\%}), followed by reduced hair volume (53.9{\%}), hair loss (34.6{\%}), and gray hair (34.6{\%}). Conclusion: PCIA is a common adverse event of breast cancer adjuvant cytotoxic chemotherapy. Clinicians should be aware of this distressing adverse event and develop supportive care strategies to counsel patients and minimize its impact on quality of life. Implications for Practice: Knowledge of permanent chemotherapy-induced alopecia, an under-reported adverse event, should lead to optimized pretherapy counseling, anticipatory coping techniques, and potential therapeutic strategies for this sequela of treatment.",
keywords = "Alopecia, Breast neoplasm, Chemotherapy, Cohort",
author = "Danbee Kang and Kim, {Im Ryung} and Choi, {Eun Kyung} and Im, {Young Hyuck} and Park, {Yeon Hee} and Ahn, {Jin Seok} and Lee, {Jeong Eon} and Nam, {Seok Jin} and Lee, {Hae Kwang} and Park, {Ji Hye} and Lee, {Dong Youn} and Lacouture, {Mario E.} and Eliseo Guallar and Juhee Cho",
year = "2018",
month = "1",
day = "1",
doi = "10.1634/theoncologist.2018-0184",
language = "English (US)",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",

}

TY - JOUR

T1 - Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer

T2 - A 3-Year Prospective Cohort Study

AU - Kang, Danbee

AU - Kim, Im Ryung

AU - Choi, Eun Kyung

AU - Im, Young Hyuck

AU - Park, Yeon Hee

AU - Ahn, Jin Seok

AU - Lee, Jeong Eon

AU - Nam, Seok Jin

AU - Lee, Hae Kwang

AU - Park, Ji Hye

AU - Lee, Dong Youn

AU - Lacouture, Mario E.

AU - Guallar, Eliseo

AU - Cho, Juhee

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Although chemotherapy-induced alopecia (CIA) is considered temporary, some patients report persistent alopecia several years after chemotherapy. There is, however, a paucity of long-term prospective data on the incidence and impact of permanent CIA (PCIA). The objective of our study was to estimate the long-term incidence of PCIA in a cohort of patients with breast cancer whose hair volume and density were measured prior to chemotherapy and who were followed for 3 years after chemotherapy. Materials and Methods: Prospective cohort study of consecutive patients ≥18 years of age with postoperative diagnosis of stage I–III breast cancer expected to receive adjuvant chemotherapy at the outpatient breast cancer clinic at the Samsung Medical Center in Seoul, Korea, from February 2012 to July 2013 (n = 61). Objective hair density and thickness were measured using a noninvasive bioengineering device. Results: The proportion of participants who had PCIA at 6 months and 3 years was 39.5% and 42.3%, respectively. PCIA was characterized in most patients by incomplete hair regrowth. Patients who received a taxane-based regimen were more likely to experience PCIA compared with patients with other types of chemotherapy. At a 3-year follow-up, hair thinning was the most common problem reported by study participants (75.0%), followed by reduced hair volume (53.9%), hair loss (34.6%), and gray hair (34.6%). Conclusion: PCIA is a common adverse event of breast cancer adjuvant cytotoxic chemotherapy. Clinicians should be aware of this distressing adverse event and develop supportive care strategies to counsel patients and minimize its impact on quality of life. Implications for Practice: Knowledge of permanent chemotherapy-induced alopecia, an under-reported adverse event, should lead to optimized pretherapy counseling, anticipatory coping techniques, and potential therapeutic strategies for this sequela of treatment.

AB - Background: Although chemotherapy-induced alopecia (CIA) is considered temporary, some patients report persistent alopecia several years after chemotherapy. There is, however, a paucity of long-term prospective data on the incidence and impact of permanent CIA (PCIA). The objective of our study was to estimate the long-term incidence of PCIA in a cohort of patients with breast cancer whose hair volume and density were measured prior to chemotherapy and who were followed for 3 years after chemotherapy. Materials and Methods: Prospective cohort study of consecutive patients ≥18 years of age with postoperative diagnosis of stage I–III breast cancer expected to receive adjuvant chemotherapy at the outpatient breast cancer clinic at the Samsung Medical Center in Seoul, Korea, from February 2012 to July 2013 (n = 61). Objective hair density and thickness were measured using a noninvasive bioengineering device. Results: The proportion of participants who had PCIA at 6 months and 3 years was 39.5% and 42.3%, respectively. PCIA was characterized in most patients by incomplete hair regrowth. Patients who received a taxane-based regimen were more likely to experience PCIA compared with patients with other types of chemotherapy. At a 3-year follow-up, hair thinning was the most common problem reported by study participants (75.0%), followed by reduced hair volume (53.9%), hair loss (34.6%), and gray hair (34.6%). Conclusion: PCIA is a common adverse event of breast cancer adjuvant cytotoxic chemotherapy. Clinicians should be aware of this distressing adverse event and develop supportive care strategies to counsel patients and minimize its impact on quality of life. Implications for Practice: Knowledge of permanent chemotherapy-induced alopecia, an under-reported adverse event, should lead to optimized pretherapy counseling, anticipatory coping techniques, and potential therapeutic strategies for this sequela of treatment.

KW - Alopecia

KW - Breast neoplasm

KW - Chemotherapy

KW - Cohort

UR - http://www.scopus.com/inward/record.url?scp=85054839546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054839546&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2018-0184

DO - 10.1634/theoncologist.2018-0184

M3 - Article

C2 - 30120165

AN - SCOPUS:85054839546

JO - Oncologist

JF - Oncologist

SN - 1083-7159

ER -